Literature DB >> 22819260

Effectiveness of heliotherapy for psoriasis clearance in low and mid-latitudinal regions: a theoretical approach.

J W Krzyścin1, J Jarosławski, B Rajewska-Więch, P S Sobolewski, J Narbutt, A Lesiak, M Pawlaczyk.   

Abstract

The action spectrum for psoriasis clearance is reconstructed taking into account the results obtained in the early 1980s. The antipsoriatic action spectrum is used for weighting the medical cabinet UV spectra, and the solar spectra measured in San Diego (USA) and Belsk (Poland). The mean cumulative antipsoriatic effective dose of 450 mJ cm(-2), due to TL-01 (UVB narrowband) tubes, is taken by a patient with skin phototype II during routine 20 phototherapy sessions carried out in a phototherapy cabinet in the Medical University of Łódz. Thus, the daily mean dose of value 22.5 mJ cm(-2) is proposed as the threshold for daily solar dose for numbers of out-door exposures to clear psoriasis. We assume that the heliotherapy will last a whole month with every day 2h exposition to the direct sunlight around local noon. The heliotherapy will be successful if weather conditions permit at least 20 days with the daily exposure over the threshold. The minimum cumulative ambient erythemal dose, necessary for psoriasis clearance, is estimated as 144 standard erythema dose (SED) for the whole heliotherapy period. We find that heliotherapy could be effectively used in March through October (San Diego) and in June through August (Belsk). Thus, the heliotherapy against psoriasis is possible not only at southern resorts but even at the mid-latitude sites.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22819260     DOI: 10.1016/j.jphotobiol.2012.06.008

Source DB:  PubMed          Journal:  J Photochem Photobiol B        ISSN: 1011-1344            Impact factor:   6.252


  1 in total

1.  Accurate surface ultraviolet radiation forecasting for clinical applications with deep neural network.

Authors:  R Raksasat; P Sri-Iesaranusorn; J Pemcharoen; P Laiwarin; S Buntoung; S Janjai; E Boontaveeyuwat; P Asawanonda; S Sriswasdi; E Chuangsuwanich
Journal:  Sci Rep       Date:  2021-03-03       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.